Immunomedics awarded patent for humanized carcinoembryonic antigen antibody.
"CEA is one of the most prevalent cancer markers known and comprises one of the most frequently tested substances shed from the tumor into the blood in a variety of cancer patients, such as those with colorectal and breast cancer," commented Cynthia L. Sullivan, President and Chief Executive Officer of Immunomedics.
Ms. Sullivan added: "Our company has been a leader in CEA research and is testing this humanized antibody, alone (unconjugated) as well as conjugated with radioisotopes (iodine-131 and yttrium-90) in several Phase I and II clinical trials involving patients with colorectal, pancreatic and breast cancer, with encouraging safety and activity observed." "This new patent
now strengthens our intellectual property in the therapeutic and diagnostic areas involving CEA," remarked Ms. Sullivan.
Immunomedics develops diagnostic imaging and therapeutic products for the detection and treatment of cancer and other serious diseases. Integral to these products are highly specific monoclonal antibodies and antibody fragments designed to deliver radioisotopes and chemotherapeutic agents to tumors and other sites of disease. Immunomedics has nine therapeutic product candidates in clinical or near clinical development and has two marketed diagnostic imaging products. The most advanced therapeutic product candidates are LymphoCide (epratuzumab), for which certain Phase II clinical trials for the treatment of non-Hodgkin's lymphoma have already been completed, and CEA-Cide (labetuzumab), which is in Phase I/II clinical trials for the treatment of certain solid tumors.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Immunomedics, Inc.|
|Comment:||Immunomedics awarded patent for humanized carcinoembryonic antigen antibody.(Immunomedics, Inc.)|
|Publication:||BIOTECH Patent News|
|Date:||Feb 1, 2004|
|Previous Article:||Neurogen, Merck agreement for pain drugs cleared.|
|Next Article:||Former Vertex patent counsel sentenced to prison for insider trading.|